skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Informa pharma logo

Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Pharma Intelligence Logo
Search Icon Pharma Report StoreRecommendationsProduct loginProductLogin
Global Search Configuration

Introduction

BRAND NEW: Our pipeline report now contains an interactive early-phase forecast model and a  chapter on early-phase opportunities within asthma – exclusive content you’ll only find at Datamonitor Healthcare.

Severe asthma remains a significant cause of mortality and morbidity and a portion of patients remain inadequately treated. Biologics in the pipeline for asthma aiming to treat this patient population. Datamonitor Healthcare has provided an in-depth analysis of pipeline products in the US, Japan and five major EU markets, including new clinical data and an evaluation of clinical and commercial drug attributes.

Click here to download your free Table of Contents >>
Click here to download your free Sample Pages >>

How will our asthma pipeline report benefit you?

  • Target unmet needs
    Understand which populations in asthma are inadequately treated and how late-stage therapies will target these patient groups, enabling you to identify where there is still room for opportunities and what needs are currently being overlooked.
  • Identify investment opportunities
    Explore the future developments in the treatment of asthma, understanding how once-daily fixed-dose inhalers such as Breo will change therapy and how asthma therapy will progress, allowing you to identify what therapies you should be investing in to gain potential commercial success within the market.
  • Gain competitive overview
    Understand how biologics will position themselves within the market and compete against each other by comparing their clinical and commercial attributes, allowing you to benchmark your product against that with the most potential for success.
  • Identify early-phase opportunities
    Access our exclusive interactive 20-year early-phase forecast model with clearly identified opportunities to assist in your decision-making.

Key questions answered:

  • What pipeline therapies are set to compete successfully in the asthma market?
  • How successful has clinical development program been for biologics so far?
  • How will targeted therapies fit into the future of treatment within the market?
http://http//www.datamonitorhealthcare.com/files/2014/10/Asthma-Pipeline-10.10.2014.pdf

Read also

  • Datamonitor Healthcare: data analysis and insight, Biomedtra...

    Pricing and reimbursement of curative therapies continues to dominate ISPOR discussions

    By Louisa Joseph

    Commentators at the ISPOR Europe 2019 conference in Copenhagen debated the challenges that exist with valuing and financing potentially curative treatments, including cell and gene therapies, and cancer immunotherapies. With several recent regulatory approvals of high-cost advanced therapy medicinal products (ATMPs), discussion has ensued in earnest on how to determine their clinical value, and whether traditional reimbursement and health technology assessment (HTA) processes are sufficient to assess these innovative treatments.

    Topics

    Read Blog

  • Datamonitor Healthcare: data analysis and insight

    Webinar: Outlook for NASH Therapies and Market Dynamics

    By Joseph Haas

    Non-alcoholic steatohepatitis (NASH) is poised to become an even greater epidemic and pharma companies of all sizes are competing to be the first to bring a NASH drug to market. Listen to an in-depth discussion about new and repurposed drug exploration treat NASH, as well as deal making, licensing and partnerships activity for the area.

    Topics Cell and gene therapy Drug Development Landscape Drug approval

    Full Video

  • Awareness, Datamonitor Healthcare: data analysis and insight

    Post-ESMO Podcast 2019

    Listen to this podcast to keep up with the latest translational science and advancements in oncology to come out of the European Society of Medical Oncology (ESMO) Congress 2019. Datmonitor Healthcare’s post-event podcast delivers every important development.

    Topics Cancer Research

    Full Podcast
;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now